AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biohit Oyj

Board/Management Information Feb 20, 2017

3304_iss_2017-02-20_f3052f0f-e511-49a3-8bb1-d0f7cfc1f3de.html

Board/Management Information

Open in Viewer

Opens in native device viewer

Disclosure 349314

Biohit Oyj - Changes board/management/auditors

Biohit Oyj’s CEO Semi Korpela will return to work on 20.2.2017

Biohit Oyj Stock Exchange Release February 20, 2017 9:29 am local time (EEST) Biohit Oyj announced on January 5, 2017 that CEO Semi Korpela would take a sick leave of approximately one month, related to pneumonia and recovery from it. Korpela has recovered from his illness and will return to work on 20.2.2017. “I am full of energy”, says CEO Semi Korpela. Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 [email protected] www.biohithealthcare.com Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.